
Swiss Federal Supreme Court: Tightened Competition Law Practice on Recommended Resale Prices – Everything Unclear?
In its decision dated 4 February 2021, the Swiss Federal Supreme Court qualified Pfizer's non-binding resale price recommendations for Viagra, a medication used to treat erectile dysfunction, as inadmissible resale price maintenance in the form of a concerted practice that is subject to direct fines, contrary to the Swiss Federal Administrative Court. The judgement already attracted a lot of attention




